
|Articles|June 25, 2007
New form of existing wake-promoting drug approved
The FDA has given the go-ahead to Cephalon Inc. to market armodafinil (Nuvigil) for the treatment of excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome, narcolepsy, and shift-work sleep disorder.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Congressional Spending Bill to Include Key PBM Contracting Reform
2
Meeting at the Crossroads: The Role and Impact of PBMs and BOPs on Pharmacists
3
Pharma, OTC Supplement Are Markets Expected to Grow Billions Come 2032
4
Q&A: New Medicare Drug Prices Proving Detrimental to Pharmacy Cashflow
5









































































































































































































